JP2020514363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514363A5 JP2020514363A5 JP2019550705A JP2019550705A JP2020514363A5 JP 2020514363 A5 JP2020514363 A5 JP 2020514363A5 JP 2019550705 A JP2019550705 A JP 2019550705A JP 2019550705 A JP2019550705 A JP 2019550705A JP 2020514363 A5 JP2020514363 A5 JP 2020514363A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024009215A JP2024050684A (ja) | 2017-03-17 | 2024-01-25 | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17161717.8 | 2017-03-17 | ||
| EP17161717 | 2017-03-17 | ||
| GB1710879.6 | 2017-07-06 | ||
| GBGB1710879.6A GB201710879D0 (en) | 2017-07-06 | 2017-07-06 | Methods and compounds for tumour-specific cell depletion |
| GBGB1714429.6A GB201714429D0 (en) | 2017-09-07 | 2017-09-07 | Compounds and methods for tumour-specific cell depletion |
| GB1714429.6 | 2017-09-07 | ||
| PCT/EP2018/056312 WO2018167104A1 (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024009215A Division JP2024050684A (ja) | 2017-03-17 | 2024-01-25 | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514363A JP2020514363A (ja) | 2020-05-21 |
| JP2020514363A5 true JP2020514363A5 (enExample) | 2021-04-30 |
Family
ID=61655786
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550705A Pending JP2020514363A (ja) | 2017-03-17 | 2018-03-13 | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ |
| JP2024009215A Pending JP2024050684A (ja) | 2017-03-17 | 2024-01-25 | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024009215A Pending JP2024050684A (ja) | 2017-03-17 | 2024-01-25 | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11879014B2 (enExample) |
| EP (1) | EP3596123B1 (enExample) |
| JP (2) | JP2020514363A (enExample) |
| KR (1) | KR20190130137A (enExample) |
| CN (1) | CN110869388B (enExample) |
| AU (1) | AU2018233976B2 (enExample) |
| BR (1) | BR112019017017A2 (enExample) |
| CA (1) | CA3056506A1 (enExample) |
| CL (1) | CL2019002624A1 (enExample) |
| CR (1) | CR20190477A (enExample) |
| DK (1) | DK3596123T3 (enExample) |
| ES (1) | ES2975063T3 (enExample) |
| FI (1) | FI3596123T3 (enExample) |
| HR (1) | HRP20240469T1 (enExample) |
| HU (1) | HUE065999T2 (enExample) |
| IL (1) | IL269081A (enExample) |
| LT (1) | LT3596123T (enExample) |
| MX (1) | MX2019010974A (enExample) |
| MY (1) | MY208220A (enExample) |
| NZ (1) | NZ756984A (enExample) |
| PE (1) | PE20191812A1 (enExample) |
| PL (1) | PL3596123T3 (enExample) |
| RS (1) | RS65351B1 (enExample) |
| SG (1) | SG11201908578YA (enExample) |
| SI (1) | SI3596123T1 (enExample) |
| WO (1) | WO2018167104A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017011592A1 (en) | 2015-07-13 | 2017-01-19 | Modular Genetics, Inc. | Generation of acyl alcohols |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| SG11202008733YA (en) * | 2018-03-13 | 2020-10-29 | Tusk Therapeutics Ltd | Anti-cd25 for tumour specific cell depletion |
| JP7619941B2 (ja) | 2018-11-14 | 2025-01-22 | アイバイオ， インク． | Ｃｄ２５抗体 |
| CN113646330A (zh) * | 2018-11-14 | 2021-11-12 | 鲁比克治疗股份有限公司 | 工程化cd25多肽及其用途 |
| US20220251232A1 (en) * | 2019-05-20 | 2022-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel anti-cd25 antibodies |
| WO2020248938A1 (zh) * | 2019-06-10 | 2020-12-17 | 山东博安生物技术有限公司 | 抗cd25抗体及其应用 |
| CA3179937A1 (en) | 2020-04-10 | 2021-10-14 | Rakuten Medical, Inc. | Phthalocyanine dye compounds, conjugates and methods of use thereof |
| EP4151655A1 (en) | 2020-05-14 | 2023-03-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| US20240002521A1 (en) * | 2020-11-20 | 2024-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd25 antibodies |
| CA3199006A1 (en) * | 2020-11-20 | 2022-05-27 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-cd25 antibodies |
| WO2022117572A2 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | An ltbr agonist in combination therapy against cancer |
| EP4288100A1 (en) * | 2021-02-02 | 2023-12-13 | Rakuten Medical, Inc. | Methods for local and systemic treatment of cancers, tumors and tumor cells |
| BR112023017638A2 (pt) | 2021-03-01 | 2023-10-10 | Hoffmann La Roche | Biomarcador, métodos para identificar um paciente com câncer e para tratar um paciente que sofre de câncer e agente anti-cd25 |
| US20240352136A1 (en) | 2021-09-02 | 2024-10-24 | Hoffmann-La Roche Inc. | Antibodies for the treatment of aml |
| WO2023208990A1 (en) | 2022-04-26 | 2023-11-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist, |
| CN115181182B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种人源化的抗cd25的单域抗体及其应用 |
| WO2024006965A1 (en) * | 2022-06-30 | 2024-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd25-specific antibodies and uses thereof |
| AU2023298151A1 (en) | 2022-07-01 | 2025-01-02 | Neurogene Inc. | Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| CN118240080A (zh) * | 2022-12-22 | 2024-06-25 | 深圳市福元生物科技有限公司 | 一种cd25单域抗体、人源化抗体、及制备方法 |
| EP4662238A1 (en) | 2023-02-06 | 2025-12-17 | F. Hoffmann-La Roche AG | Combination therapy and uses thereof |
| CN116087499B (zh) * | 2023-02-20 | 2023-10-31 | 深圳裕康医学检验实验室 | 一种癌样本的染色方法及试剂盒 |
| CN120314588B (zh) * | 2025-05-21 | 2025-10-17 | 成都蓉生药业有限责任公司 | 一种人免疫球蛋白抗体依赖性细胞介导的吞噬作用生物学活性的检测方法和检测试剂盒 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| BRPI0316282B8 (pt) | 2002-11-15 | 2021-05-25 | Genmab As | anticorpo humano isolado monoclonal, composição, imunoconjugado, molécula biespecífica ou multiespecífica, método e conjunto de diagnóstico para detectar a presença de antígeno cd25 ou uma célula que expressa cd25, e, vetor de expressão |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| CA2656224C (en) | 2006-06-26 | 2018-01-09 | Macrogenics, Inc. | Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof |
| JP2009542592A (ja) | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法 |
| EA201201533A1 (ru) | 2006-08-18 | 2014-11-28 | Новартис Аг | Prlr-специфическое антитело и его применения |
| RU2391401C2 (ru) | 2008-02-12 | 2010-06-10 | Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" | СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| CA2742968C (en) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| MY160680A (en) | 2009-09-22 | 2017-03-15 | Probiogen Ag | Process for producing molecules containing specialized glycan structures |
| JP5595517B2 (ja) * | 2009-12-21 | 2014-09-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ＦｃγＲマウス |
| TWI513466B (zh) | 2010-01-20 | 2015-12-21 | Boehringer Ingelheim Int | 抗凝血劑解毒劑 |
| CN103168104B (zh) | 2010-07-22 | 2016-09-28 | 加利福尼亚大学董事会 | 抗肿瘤抗原抗体及其使用方法 |
| MX2015012551A (es) | 2013-03-15 | 2016-10-26 | Abbvie Biotechnology Ltd | Anticuerpos anti-cd25 y sus usos. |
| EP3421495A3 (en) * | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| RU2015144033A (ru) | 2013-03-15 | 2017-04-26 | Эббви Байотекнолоджи Лтд. | Антитела против cd25 и их применения |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| RU2759970C2 (ru) | 2016-04-07 | 2021-11-19 | Кансер Ресёрч Текнолоджи Лимитед | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК |
| EA201991142A1 (ru) | 2016-11-08 | 2019-10-31 | Варианты il-2 для лечения аутоиммунных заболеваний | |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| UA129536C2 (uk) | 2018-03-13 | 2025-05-28 | Туск Терап'Ютікс Лтд | Анти-cd25 для виснаження пухлиноспецифічних клітин |
-
2018
- 2018-03-03 US US16/494,962 patent/US11879014B2/en active Active
- 2018-03-13 HU HUE18711313A patent/HUE065999T2/hu unknown
- 2018-03-13 CR CR20190477A patent/CR20190477A/es unknown
- 2018-03-13 KR KR1020197030283A patent/KR20190130137A/ko not_active Ceased
- 2018-03-13 FI FIEP18711313.9T patent/FI3596123T3/fi active
- 2018-03-13 BR BR112019017017A patent/BR112019017017A2/pt unknown
- 2018-03-13 SI SI201831085T patent/SI3596123T1/sl unknown
- 2018-03-13 JP JP2019550705A patent/JP2020514363A/ja active Pending
- 2018-03-13 MX MX2019010974A patent/MX2019010974A/es unknown
- 2018-03-13 RS RS20240376A patent/RS65351B1/sr unknown
- 2018-03-13 PE PE2019001847A patent/PE20191812A1/es unknown
- 2018-03-13 CN CN201880018976.8A patent/CN110869388B/zh active Active
- 2018-03-13 PL PL18711313.9T patent/PL3596123T3/pl unknown
- 2018-03-13 WO PCT/EP2018/056312 patent/WO2018167104A1/en not_active Ceased
- 2018-03-13 MY MYPI2019005313A patent/MY208220A/en unknown
- 2018-03-13 NZ NZ756984A patent/NZ756984A/en unknown
- 2018-03-13 DK DK18711313.9T patent/DK3596123T3/da active
- 2018-03-13 CA CA3056506A patent/CA3056506A1/en active Pending
- 2018-03-13 ES ES18711313T patent/ES2975063T3/es active Active
- 2018-03-13 HR HRP20240469TT patent/HRP20240469T1/hr unknown
- 2018-03-13 LT LTEPPCT/EP2018/056312T patent/LT3596123T/lt unknown
- 2018-03-13 AU AU2018233976A patent/AU2018233976B2/en active Active
- 2018-03-13 EP EP18711313.9A patent/EP3596123B1/en active Active
- 2018-03-13 SG SG11201908578Y patent/SG11201908578YA/en unknown
-
2019
- 2019-09-02 IL IL26908119A patent/IL269081A/en unknown
- 2019-09-13 CL CL2019002624A patent/CL2019002624A1/es unknown
-
2024
- 2024-01-25 JP JP2024009215A patent/JP2024050684A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514363A5 (enExample) | ||
| JP7575100B2 (ja) | 免疫細胞活性化のための二重特異性抗体 | |
| JP7397055B2 (ja) | Ｃｄ１３７及びｏｘ４０に結合する抗体分子 | |
| JP2024050684A (ja) | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ | |
| US20220025050A1 (en) | Bifunctional molecule directed against human pd-1 | |
| ES2980623T3 (es) | Anticuerpos de unión a CD3 | |
| CN109641049B (zh) | Cd3结合抗体 | |
| JP7225135B2 (ja) | 腫瘍特異的細胞枯渇のための化合物及び方法 | |
| JP2019513725A5 (enExample) | ||
| JP2020521759A (ja) | 免疫トレランスを調節するための多機能性の抗体−リガンド・トラップ | |
| IL259495B2 (en) | Antibodies and methods for using them | |
| JP2017511379A (ja) | アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用 | |
| CN114269785A (zh) | 免疫刺激性多聚体结合分子 | |
| KR20180037924A (ko) | 항-ctla-4 항체 및 이의 사용 방법 | |
| JP7680208B2 (ja) | 抗ｃｄ２７抗体およびその使用 | |
| JP2016513467A5 (enExample) | ||
| CA3106051A1 (en) | Fc binding fragments comprising an ox40 antigen-binding site | |
| JP2021501801A (ja) | 癌の処置に用いるための免疫刺激アゴニスト抗体 | |
| KR20210110818A (ko) | Rank 길항제 및 이에 대한 용도 | |
| WO2022212876A1 (en) | Antibodies against cleaved cdcp1 and uses thereof | |
| JP2022553129A (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| JP7486616B2 (ja) | Ｂｔｌａ抗体 | |
| US20250002600A1 (en) | Multispecific binding agents against pd-l1 and cd137 in combination therapy | |
| US20250101104A1 (en) | Bispecific molecule with tunable affinity to a targeted antigen | |
| CA3259108A1 (en) | Attenuated Anti-PD1-IL2 Immunoconjugates and Their Uses |